TOKIWA-Bio is a gene-cell therapy and regenerative medicine product development company which has developed Stealth RNA Vector(SRV) an innovative technology of gene expression system. The SRV is the world-first RNA vector stabilized in cytoplasm and capable to install at least 10 genes on single vector.
Projects of Expression Vector Development
The iPS cells is produced in all over the world, but there are few technologies to control expression of plural genes. SeVdp vector is distributed from AIST to all over the world for evaluation, and got a high evaluation in every facilities.
The next aim is manufacture of clinical-use iPS cells safely, and it is accomplished by Tokiwa-Bio’s innovation which evolved more.
Projects of Device development
It is possible to produce full automatic devices of iPS cells from monocyte by using Tokiwa-Bio’s innovation.
Projects of Cell Drug Development
● Various functional cells derived from iPS cells for regenerative medicine
● Vectors that can reprogram target cells to purpose cells directly
● Somatic cells for transfusions that express plural gene efficiently